UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals on Recent Market Weakness

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Wednesday, Canaccord Genuity analyst John Newman assumed coverage on

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

NPS Pharmaceuticals

(NASDAQ: NPSP) with a Buy rating and $42.00 price target.In the report, Canaccord Genuity noted, “We recommend buying NPSP on recent market weakness based on its three high-priced orphan drugs with ongoing launches and upcoming FDA approval in 2014. We expect the US Gattex and EU Restive launches to perform well in 2014 and believe Natpara revenue estimates remain low.”NPS Pharmaceuticals closed on Tuesday at $23.38.